Icosavax, a company that is involved in developing vaccines against infectious diseases, has launched a USD51m Series A financing, led by Qiming Venture Partners USA and joined by Adams Street Partners, Sanofi Ventures and NanoDimension, with continuing support from its seed investors, it was reported on Friday.
The funds will be utilised to advance the Phase 1b clinical studies of the company's first vaccine candidate, IVX-121, intended for the treatment of respiratory syncytial virus for older adults.
Adam Simpson, chief executive officer of Icosavax, said, 'Working closely with the Institute for Protein Design, we started Icosavax with seed funding from its philanthropic supporters. This support allowed us to assemble a world-class team and to help translate the scientific insights from IPD into IVX-121, our lead candidate for RSV. We are thrilled with the quality of the investor syndicate we have built who provide both significant expertise and financial support to enable advancement of IVX-121 into the clinic and the application of our VLP technology to a whole class of vaccine targets with significant unmet medical needs.'
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial